Eli Lilly and Company (LLY)
Cash ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and cash equivalents | US$ in thousands | 3,268,400 | 3,369,000 | 3,223,600 | 2,460,200 | 2,818,600 | 2,380,800 | 2,694,500 | 3,545,900 | 2,067,000 | 2,617,400 | 2,622,900 | 2,459,200 | 3,818,500 | 3,788,200 | 3,220,000 | 3,002,400 | 3,657,100 | 3,595,300 | 2,365,100 | 1,699,000 |
Short-term investments | US$ in thousands | 154,800 | 149,400 | 140,400 | 126,100 | 109,100 | 113,100 | 134,600 | 123,400 | 144,800 | 124,700 | 113,800 | 109,100 | 90,100 | 37,100 | 51,200 | 49,000 | 24,200 | 35,000 | 22,800 | 78,400 |
Total current liabilities | US$ in thousands | 28,376,600 | 24,674,100 | 27,121,200 | 18,598,100 | 27,293,200 | 21,998,200 | 18,915,000 | 16,010,000 | 17,138,200 | 15,652,800 | 15,620,600 | 13,386,000 | 15,052,700 | 13,682,000 | 15,093,200 | 11,714,200 | 12,481,600 | 11,976,900 | 11,988,500 | 12,610,200 |
Cash ratio | 0.12 | 0.14 | 0.12 | 0.14 | 0.11 | 0.11 | 0.15 | 0.23 | 0.13 | 0.18 | 0.18 | 0.19 | 0.26 | 0.28 | 0.22 | 0.26 | 0.29 | 0.30 | 0.20 | 0.14 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($3,268,400K
+ $154,800K)
÷ $28,376,600K
= 0.12
The cash ratio of Eli Lilly and Company has fluctuated over the periods provided. It was relatively low at around 0.14 to 0.20 in the first half of 2020, indicating that the company had limited cash readily available to cover its short-term obligations. However, the ratio improved in the latter half of 2020 and into 2021, reaching a peak of 0.30 in September 2020, suggesting stronger liquidity position.
Subsequently, the cash ratio dipped back to the mid-0.20s and 0.10s range in the following periods, implying a slight decline in the company's ability to meet its short-term liabilities solely with cash on hand. By the end of 2024, the cash ratio had leveled off around 0.12 to 0.14, indicating that Eli Lilly may need to monitor its liquidity position to ensure it has enough cash to cover its short-term obligations.
Peer comparison
Dec 31, 2024